Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845676 · ClinicalTrials.gov registry record · Phase 4
Treatment of Acute Hepatitis C Virus in HIV Co-Infection
A Phase 4 study of HIV Infections and Hepatitis C, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00845676: Completed Phase 4 study of HIV Infections and Hepatitis C, sponsored by University of California, San Francisco.
NCT00845676 is a Phase 4 study of HIV Infections and Hepatitis C that has completed, run by University of California, San Francisco. The registered enrollment target is 21 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00845676, a Phase 4 study of HIV Infections and Hepatitis C, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved responses to HCV therapy with a shorter duration of infection.
Primary Outcome
Proportion of subjects achieving a sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after completion of treatment
Conditions Studied
Interventions
- DRUG Pegylated interferon alfa-2a + Ribavirin
Study Locations (1)
California
- San Francisco General Hospital/UCSF - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
What the finished NCT00845676 record still lists
NCT00845676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Pegylated interferon alfa-2a + Ribavirin is the first listed.
NCT00845676 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00845676 about?
NCT00845676 is a clinical study titled "Treatment of Acute Hepatitis C Virus in HIV Co-Infection". This study is designed to test the hypothesis that treatment of hepatitis C virus (HCV) infection during the first 6 months after acquiring HCV among people who already have pre-existing HIV infection will result in improved responses to HCV therapy with a shorter duration of infection.
What is the current status of trial NCT00845676?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2008-03. Estimated completion is 2013-12.
What conditions does trial NCT00845676 study?
This clinical trial studies the following conditions: HIV Infections, Hepatitis C, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT00845676?
The interventions under investigation include: Pegylated interferon alfa-2a + Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00845676?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00845676 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00845676's enrollment target sits among peer trials
21 482nd of 542 higher than 57 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia